semaglutide cause joint pain for Weight Loss and Ozempic and GLP-1 Drugs: Risk

This narrative review synthesizes data from randomized controlled trials (RCTs) and real-world evidence (RWE) on Wegovy (semaglutide 2.4 mg, a recombinant DNA-derived GLP-1RA) in obesity with CVD, with a focus on SELECT, mediation analyses suggesting weight-independent CV effects, and outcomes in obesity-related HFpEF

Our latest Q&A breaks down the answers, straight from the questions we hear most often.

CONTENT: PRESENTATION SIZE: 1 vial in a box

Patients were stratified according to exposure (n=106,454) or non-exposure (n=317,698) to once-weekly semaglutide, and incidence rates and hazard ratios (HR) of NAION were estimated in a multivariable Cox proportional hazard regression model

GLP-1 medications are reshaping weight loss treatment

The Ozempic pill (fka Rybelsus) (oral semaglutide) is the first and only oral GLP-1 receptor agonist approved by the FDA